Soleno Therapeutics to Participate in Two Upcoming Investor Conferences

REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel titled, "How Will Orphan & Ultra-Orphan Drugs Stand up Against Pricing Uncertainties?", and provide a corporate update, at the 31^st Annual ROTH Conference, taking place March 17-19, 2019, in Dana Point, CA. 

Dr. Bhatnagar will also present a corporate overview at the Oppenheimer & Co. 29^th Annual Healthcare Conference, taking place March 19-20, 2019, in New York, NY.  The presentation will take place on Wednesday, March 20, at 10:55 AM ET, and will be webcast live at https://www.veracast.com/webcasts/opco/healthcare2019/04207604863.cfm.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit www.soleno.life.

CONTACT:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578